JonesResearch analyst Debanjana Chatterjee initiated coverage of Contineum (CTNM) with a Buy rating and $23 price target The company’s lead clinical-stage asset is PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, the analyst tells investors in a research note. The firm believes PIPE-791 appears likely to show “best-in-class” efficacy and safety.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM: